The Therapeutic Potential of VEGFC in Experimental Diabetic Nephropathy

Foster, R R (Principal Investigator)

Bristol Medical School (THS)

Status	Finished
Effective start/end date	1/01/13 → 1/01/14

Research Groups and Themes

Bristol Heart Institute

1 Article (Academic Journal)

VEGFC reduces glomerular albumin permeability and protects against alterations in VEGF receptor expression in diabetic nephropathy
Onions, K. L., Gamez, M., Buckner, N. R., Baker, S. L., Betteridge, K. B., Desideri, S., Dallyn, B. P., Ramnath, R. D., Neal, C. R., Farmer, L. K., Mathieson, P. W., Gnudi, L., Alitalo, K., Bates, D. O., Salmon, A. H. J., Welsh, G. I., Satchell, S. C. & Foster, R. R., 1 Jan 2019, In: Diabetes. 68, 1, p. 172-187 16 p.
Research output: Contribution to journal › Article (Academic Journal) › peer-review

Open Access
File
51 Citations (Scopus)

351 Downloads (Pure)